Next-generation sequencing or whole exome sequencing of 29 of the 32 cases of AML enrolled in the phase II venetoclax monotherapy study suggested that SRSF2/ZRSR2 and IDH1/2 mutations may predict sensitivity to venetoclax therapy in AML[138,159]. This evidence concerns the gene SRSF2 and acute myeloid leukemia.